{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:21:38Z","timestamp":1791354098088,"version":"4.3.1"},"reference-count":98,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.beha.2013.09.006","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T16:07:15Z","timestamp":1380643635000},"page":"387-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Chronic myelomonocytic leukemia: Myelodysplastic or myeloproliferative?"],"prefix":"10.1016","volume":"26","author":[{"given":"Raphael","family":"Itzkson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Solary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.beha.2013.09.006_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2013.09.006_bib2","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.leukres.2012.06.009","article-title":"Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): a population-based study, 1993\u20132007","volume":"36","author":"Osca-Gelis","year":"2012","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.beha.2013.09.006_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.beha.2013.09.006_bib4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2141.2010.08525.x","article-title":"Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia","volume":"152","author":"Loh","year":"2011","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2013.09.006_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.beha.2013.09.006_bib6","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1158\/0008-5472.CAN-08-2754","article-title":"250\u00a0K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies","volume":"68","author":"Dunbar","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.beha.2013.09.006_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2009-05-224352","article-title":"Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia","volume":"115","author":"Droin","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.006_bib8","first-page":"3997","article-title":"Myeloid-derived suppressive cells belonging to the leukemic clone account for immunosuppression in CMML","author":"Droin","year":"2010","journal-title":"Blood ASH Ann Meet"},{"issue":"3","key":"10.1016\/j.beha.2013.09.006_bib9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.beha.2013.09.006_bib10","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2003-09-3192","article-title":"Engraftment of NOD\/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome","volume":"103","author":"Thanopoulou","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2013.09.006_bib11","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1073\/pnas.0712391105","article-title":"Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function","volume":"105","author":"Marcondes","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7290","key":"10.1016\/j.beha.2013.09.006_bib12","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature08851","article-title":"Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia","volume":"464","author":"Raaijmakers","year":"2010","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.beha.2013.09.006_bib13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V77.5.925.925","article-title":"Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors","volume":"77","author":"Emanuel","year":"1991","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.beha.2013.09.006_bib14","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2013.09.006_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00282-997-0041-4","article-title":"Chronic myelomonocytic leukemia: from biology to therapy","volume":"39","author":"Cambier","year":"1997","journal-title":"Hematol Cell Ther"},{"issue":"10","key":"10.1016\/j.beha.2013.09.006_bib16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0301-472X(02)00903-7","article-title":"Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in\u00a0vitro and in\u00a0vivo","volume":"30","author":"Ramshaw","year":"2002","journal-title":"Exp Hematol"},{"issue":"21","key":"10.1016\/j.beha.2013.09.006_bib17","first-page":"309","article-title":"Two distinct mechanisms contribute to granulomonocytic hyperplasia in chronic myelomonocytic leukemias (CMML)","volume":"120","author":"Itzykson","year":"2012","journal-title":"ASH Annu Meet Abstr"},{"issue":"24","key":"10.1016\/j.beha.2013.09.006_bib18","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"7346","key":"10.1016\/j.beha.2013.09.006_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature09999","article-title":"A\u00a0novel tumour-suppressor function for the Notch pathway in myeloid leukaemia","volume":"473","author":"Klinakis","year":"2011","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.beha.2013.09.006_bib20","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2013.09.006_bib21","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2013.09.006_bib22","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"5929","key":"10.1016\/j.beha.2013.09.006_bib23","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Science"},{"issue":"7325","key":"10.1016\/j.beha.2013.09.006_bib24","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.beha.2013.09.006_bib25","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.cell.2011.11.054","article-title":"Mbd3\/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells","volume":"147","author":"Yildirim","year":"2011","journal-title":"Cell"},{"issue":"7433","key":"10.1016\/j.beha.2013.09.006_bib26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature11742","article-title":"TET2 promotes histone O-GlcNAcylation during gene transcription","volume":"493","author":"Chen","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.beha.2013.09.006_bib27","doi-asserted-by":"crossref","first-page":"e31605","DOI":"10.1371\/journal.pone.0031605","article-title":"TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia","volume":"7","author":"Perez","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.beha.2013.09.006_bib28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4161\/epi.7.2.19015","article-title":"Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia","volume":"7","author":"Yamazaki","year":"2012","journal-title":"Epigenetics"},{"issue":"9","key":"10.1016\/j.beha.2013.09.006_bib29","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1182\/blood-2010-12-324707","article-title":"Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors","volume":"118","author":"Pronier","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2013.09.006_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.beha.2013.09.006_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell."},{"issue":"12","key":"10.1016\/j.beha.2013.09.006_bib32","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"issue":"149","key":"10.1016\/j.beha.2013.09.006_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004315","article-title":"Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia","volume":"4","author":"Jan","year":"2012","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.beha.2013.09.006_bib34","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat Genet"},{"issue":"7367","key":"10.1016\/j.beha.2013.09.006_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.beha.2013.09.006_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ng.1031","article-title":"Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes","volume":"44","author":"Graubert","year":"2012","journal-title":"Nat Genet"},{"issue":"15","key":"10.1016\/j.beha.2013.09.006_bib37","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1128\/MCB.00288-07","article-title":"Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis","volume":"27","author":"Xiao","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.beha.2013.09.006_bib38","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1042\/BST0381251","article-title":"Cross-talk in transcription, splicing and chromatin: who makes the first call?","volume":"38","author":"Alexander","year":"2010","journal-title":"Biochem Soc Trans"},{"issue":"8","key":"10.1016\/j.beha.2013.09.006_bib39","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.beha.2013.09.006_bib40","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat Genet"},{"issue":"14","key":"10.1016\/j.beha.2013.09.006_bib41","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2013.09.006_bib42","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2011-07-367243","article-title":"Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms","volume":"119","author":"Score","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2013.09.006_bib43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell."},{"issue":"6","key":"10.1016\/j.beha.2013.09.006_bib44","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","article-title":"Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"145","author":"Gelsi-Boyer","year":"2009","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.beha.2013.09.006_bib45","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/leu.2010.144","article-title":"The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration","volume":"24","author":"Abdel-Wahab","year":"2010","journal-title":"Leukemia"},{"issue":"7295","key":"10.1016\/j.beha.2013.09.006_bib46","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"issue":"6101","key":"10.1016\/j.beha.2013.09.006_bib47","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1126\/science.1221711","article-title":"Loss of the tumor suppressor BAP1 causes myeloid transformation","volume":"337","author":"Dey","year":"2012","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.beha.2013.09.006_bib48","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2013.09.006_bib49","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.leu.2401044","article-title":"RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up","volume":"12","author":"Padua","year":"1998","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2013.09.006_bib50","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood-2008-04-152157","article-title":"High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients","volume":"113","author":"Tyner","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2013.09.006_bib51","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1073\/pnas.0307203101","article-title":"Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder","volume":"101","author":"Braun","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.beha.2013.09.006_bib52","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1172\/JCI20476","article-title":"Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease","volume":"113","author":"Chan","year":"2004","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.beha.2013.09.006_bib53","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2006-09-047530","article-title":"K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem\/progenitor cells","volume":"109","author":"Van Meter","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2013.09.006_bib54","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood-2006-01-013490","article-title":"Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in\u00a0vivo","volume":"108","author":"Braun","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2013.09.006_bib55","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1371\/journal.pbio.1000059","article-title":"Oncogenic Kras initiates leukemia in hematopoietic stem cells","volume":"7","author":"Sabnis","year":"2009","journal-title":"PLoS Biol"},{"issue":"8","key":"10.1016\/j.beha.2013.09.006_bib56","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.beha.2013.09.006_bib57","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.beha.2013.09.006_bib58","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1200\/JCO.2009.23.7503","article-title":"Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies","volume":"27","author":"Makishima","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2013.09.006_bib59","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nrm1762","article-title":"The Cbl interactome and its functions","volume":"6","author":"Schmidt","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.beha.2013.09.006_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","author":"Sanada","year":"2009","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.beha.2013.09.006_bib61","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/ng.641","article-title":"Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia","volume":"42","author":"Niemeyer","year":"2010","journal-title":"Nat Genet"},{"issue":"76","key":"10.1016\/j.beha.2013.09.006_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001069","article-title":"A\u00a0MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice","volume":"3","author":"Lyubynska","year":"2011","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.beha.2013.09.006_bib63","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"JAK2 mutation 1849G\u00a0>\u00a0T is rare in acute leukemias but can be found in CMML, philadelphia chromosome-negative CML, and megakaryocytic leukemia","volume":"106","author":"Jelinek","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2013.09.006_bib64","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ccr.2007.08.031","article-title":"FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia","volume":"12","author":"Lee","year":"2007","journal-title":"Cancer Cell."},{"issue":"6","key":"10.1016\/j.beha.2013.09.006_bib65","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1182\/blood-2005-08-3329","article-title":"Recent insights into the role of Notch signaling in tumorigenesis","volume":"107","author":"Leong","year":"2006","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2013.09.006_bib66","first-page":"782","article-title":"Recurrent mutations of multiple components of cohesin complex in myeloid neoplasms","volume":"120","author":"Kon","year":"2012","journal-title":"ASH Annu Meet Abstr"},{"issue":"2","key":"10.1016\/j.beha.2013.09.006_bib67","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.gde.2011.11.003","article-title":"Cohesin and chromatin organisation","volume":"22","author":"Seitan","year":"2012","journal-title":"Curr Opin Genet Dev"},{"issue":"1","key":"10.1016\/j.beha.2013.09.006_bib68","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.beha.2013.09.006_bib69","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1172\/JCI45213","article-title":"Transcription intermediary factor 1gamma is a tumor suppressor in mouse and human chronic myelomonocytic leukemia","volume":"121","author":"Aucagne","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beha.2013.09.006_bib70","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase II trial","volume":"118","author":"Braun","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2013.09.006_bib71","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/1042819042000207271","article-title":"Risk assessment in chronic myelomonocytic leukemia (CMML)","volume":"45","author":"Germing","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.beha.2013.09.006_bib72","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1200\/JCO.1988.6.9.1417","article-title":"Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases","volume":"6","author":"Fenaux","year":"1988","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2013.09.006_bib73","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2141.1988.tb04173.x","article-title":"Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival","volume":"68","author":"Worsley","year":"1988","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.beha.2013.09.006_bib74","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0145-2126(02)00021-8","article-title":"Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center","volume":"26","author":"Gonzalez-Medina","year":"2002","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.beha.2013.09.006_bib75","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood-2002-01-0330","article-title":"New prognostic parameters for chronic myelomonocytic leukemia","volume":"100","author":"Germing","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2013.09.006_bib76","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2013.09.006_bib77","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.beha.2013.09.006_bib78","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2013.09.006_bib79","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood-2010-07-295857","article-title":"Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies","volume":"117","author":"Tiu","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2013.09.006_bib80","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2141.2012.09069.x","article-title":"New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients","volume":"157","author":"Bou Samra","year":"2012","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.beha.2013.09.006_bib81","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3324\/haematol.2012.065375","article-title":"Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative disorders: an analysis of 636 cases","volume":"97","author":"Schnittger","year":"2012","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.beha.2013.09.006_bib82","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2011.10","article-title":"Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2013.09.006_bib83","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2009.011205","article-title":"TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia","volume":"94","author":"Kosmider","year":"2009","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.beha.2013.09.006_bib84","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1182\/blood-2009-02-205690","article-title":"Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic\/myeloproliferative neoplasms","volume":"113","author":"Jankowska","year":"2009","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2013.09.006_bib85","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","article-title":"Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2013.09.006_bib86","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2012.064048","article-title":"Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia","volume":"98","author":"Kar","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.beha.2013.09.006_bib87","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia","volume":"151","author":"Gelsi-Boyer","year":"2010","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2013.09.006_bib88","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/bmt.2011.141","article-title":"Current status of allogeneic HST for chronic myelomonocytic leukemia","volume":"47","author":"Cheng","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.beha.2013.09.006_bib89","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ejh.12073","article-title":"Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"90","author":"Park","year":"2013","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2013.09.006_bib90","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2141.1991.tb08616.x","article-title":"Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy","volume":"77","author":"Fenaux","year":"1991","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.beha.2013.09.006_bib91","first-page":"1129","article-title":"Low-dose cytosine arabinoside in adult chronic myelomonocytic leukemia","volume":"5","author":"Fenaux","year":"1987","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2013.09.006_bib92","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.V88.7.2473.bloodjournal8872473","article-title":"Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"88","author":"Beran","year":"1996","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2013.09.006_bib93","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2006-07-035725","article-title":"A\u00a0multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome","volume":"109","author":"Fenaux","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2013.09.006_bib94","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A\u00a0randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.006_bib95","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.beha.2013.09.006_bib96","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.leukres.2013.01.004","article-title":"Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine","volume":"37","author":"Ad\u00e8s","year":"2013","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.beha.2013.09.006_bib97","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cncr.22457","article-title":"Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia","volume":"109","author":"Aribi","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.beha.2013.09.006_bib98","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)","volume":"32","author":"Wijermans","year":"2008","journal-title":"Leuk Res"}],"updated-by":[{"DOI":"10.1016\/j.beha.2014.02.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000}}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692613000546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692613000546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:04:45Z","timestamp":1761498285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692613000546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1521692613000546"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2013.09.006","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic myelomonocytic leukemia: Myelodysplastic or myeloproliferative?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2013.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}